SINGAPORE, Feb. 1, 2017 /PRNewswire/ -- Vela Diagnostics announced today that it reports a triple revenue growth in FY16. This is mainly driven by market outreach expansion, innovation, new customer acquisitions and an expansion in sales coverage across the globe.
Vela Diagnostics is proud to highlight the launch of the Sentosa® Next-Generation Sequencing (NGS) workflow, the attainment of regulatory approvals and successful completion of corporate development activities.
In the space of regulatory approvals in the 2016 - the following milestones were achieved. In May and June 2016, the NGS-based Sentosa® SQ HCV Genotyping Assay, which includes drug resistance detection, was approved by the Australian Therapeutic Goods Administration (TGA) for in-vitro diagnostic use and received the European CE mark for in-vitro diagnostic use respectively. Currently, Vela Diagnostics is the only company in the market, providing an end-to-end NGS-based IVD oncology workflow with various regulatory approvals for NSCLC and CRC.
In September 2016, the Sentosa® SA ZIKV RT-PCR Test has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration for zika virus detection.
From the corporate development perspective Vela Diagnostics has completed the acquisition of LifeCode Inc; and a full transition into the Vela Diagnostics portfolio under the name of Vela Genomics has been completed. Vela Genomics is a clinical interpretation reporting service that provides clinicians with a complete Patient-to-Treatments matching solution, therefore empowering clinicians with information on available treatment options and up-to-date relevant clinical trials.
Vela Diagnostics aims to accelerate the adoption of Next-Generation Sequencing (NGS) in routine clinical diagnostics.
About Vela Diagnostics
Vela Diagnostics provides a broad menu of molecular diagnostic tests, consolidated on its automated Sentosa® workflow system. Currently Vela Diagnostics offers 25 CE-IVD approved PCR tests and 5 CE-IVD approved NGS panels validated with 21 different sample types and open-channel capabilities.
The company was founded in 2011 with the vision of providing in-vitro diagnostic solutions for customers to achieve improved patient management. Vela is a privately owned Group of Companies headquartered in Singapore. The Asia Pacific, European, Australian and North American commercial operations of the Group are based in Singapore, Hamburg, Sydney and New Jersey, respectively. Vela Diagnostics also operates Global R&D and Global Manufacturing facilities in Singapore. For more information, please visit us at www.veladx.com
